Hikma acquires Insys’ naloxone, epinephrine nasal sprays
Hikma is set to acquire Insys Therapeutics’complementary manufacturing platform and two pipeline products.
As part of Insys filing for chapter 11 bankruptcy protection in June, the company has undertaken the process of selling off its assets — several of which Hikma will be walking away with. Hikma will be acquiring Insys’ unit-dose nasal and sublingual spray manufacturing equipment, as long as its naloxone nasal spray and epinephrine nasal spray, both of which currently are in the pipeline.
“Hikma is the largest supplier of generic nasal sprays in the United States and we have been looking for ways to build upon our strong manufacturing platform and expand our product portfolio,” Hikma president of generics Brian Hoffmann said. “This acquisition adds unit-dose nasal spray manufacturing equipment, as well as two complex products to our pipeline. This new technology expands our existing nasal spray capabilities, creating a comprehensive platform, which we can leverage for both internal and partnership programs.”
Naloxone is used to block or reverse the effect of opioids. Narcan Nasal Sprayis the only nasal form of naloxone on the market. Narcan had a market value of approximately $164 million in the 12 months ended in June 2019, according to IQVIA.
Epinephrine is used to treat a number of conditions, including anaphylaxis, cardiac arrest, and superficial bleeding. Epinephrine auto-injectors had a market value of approximately $4.3 billion in the 12 months ended in June 2019, according to IQVIA. Currently, there are no approved nasal forms of epinephrine in the United States
No comments found